Moderate riskFDA DrugClass II

Mylan acamprosate calcium tablets recalled for failed dissolution

Mylan Pharmaceuticals is recalling one lot of Acamprosate Calcium 333 mg delayed-release tablets because they failed to meet dissolution specifications—meaning the tablets may not break down and release the medication as intended in the body. This could result in ineffective treatment. No injuries have been reported.

From the FDA notice · Read the official notice ↗ · All Mylan recalls

What to do

  1. Check if your Acamprosate Calcium matches lot #3227809 (expiring 10/2026, NDC 0378-6333-80).
  2. Contact your pharmacy or doctor if you have this lot; do not stop taking your medication without medical guidance.
  3. Your pharmacy or doctor can provide a replacement or alternative treatment.

Is yours affected?

Compare your label or packaging with the recalled product.

Product
Acamprosate Calcium, Delayed-Release Tablets, 333 mg, 180 tablets bottles, Rx only, Mylan Pharmaceuticals Inc., Manufactured for: Mylan Pharmaceuticals Inc., Morgantown, WV 266505, NDC 0378-6333-80.
Sold in
Nationwide
Made for
Adults (0 months and older)

Details

Illnesses reported
None reported
Manufactured in
3711 Collins Ferry Rd, Morgantown, WV, United States
Classification
Class II
Recall number
D-0774-2026

In the FDA's words

Description
Acamprosate Calcium, Delayed-Release Tablets, 333 mg, 180 tablets bottles, Rx only, Mylan Pharmaceuticals Inc., Manufactured for: Mylan Pharmaceuticals Inc., Morgantown, WV 266505, NDC 0378-6333-80. Failed Dissolution Specifications Lot# 3227809; Expiry:10/2026; NDC #: 0378-6333-80 Distribution: US Nationwide.
Hazard
Failed Dissolution Specifications

More from Mylan

See all

Related topics

PotencyDrugsSold nationwideMore from FDA Drug